Allergy Alert: Popular Cetirizine Recalled Over Dangerous Ranitidine Contamination

Heads up, allergy sufferers: the FDA has issued a nationwide recall for specific lots of generic cetirizine hydrochloride 5 mg tablets, a common over-the-counter antihistamine. The reason? A concerning discovery of possible cross-contamination with ranitidine during manufacturing, which could trigger severe, life-threatening allergic reactions in some individuals. This move comes after a pharmacy technician spotted unusual red discoloration on tablets, sparking immediate safety concerns. This isn't just about a manufacturing mix-up; it shines a spotlight on persistent drug safety issues. Ranitidine, a former heartburn staple, was itself subject to massive recalls starting in 2019 due to contamination with N-Nitrosodimethylamine (NDMA), a probable human carcinogen. While the current cetirizine recall specifically highlights the risk of hypersensitivity to ranitidine ingredients, the broader context underscores the critical importance of stringent quality control in pharmaceutical manufacturing. Unique Pharmaceutical Laboratories manufactured the affected tablets, which were distributed nationwide by Rising Pharma Holdings Inc.. If you have cetirizine hydrochloride 5 mg tablets at home, check the lot numbers immediately against the FDA recall notice; the affected lots are GY825029, GY825030, GY825031, and GY825032, all expiring in October 2028. The FDA advises consumers with these recalled products to consult their healthcare provider for guidance on alternative treatments. This incident is a stark reminder that even seemingly routine medications require constant vigilance from regulators and manufacturers to ensure public safety.